Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 multicenter study of subcutaneous daratumumab in combination with standard therapies for multiple myeloma
MOH_2018-05-02_002355Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of daratumumab and hyaluronidase in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Clinical benefit / treatment response. Started Jan 2018; status: completed.
02
Drugs
daratumumabhyaluronidase
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2018-05-02_002355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-02_002355.